Abstract The rise of generative artificial intelligence (GenAI) has ushered in a new era in scientific publishing. Alongside its benefits, it has also introduced new challenges, particularly in relation to publication fraud. This editorial outlines the current position of the British Journal of Pharmacology on the use of AI in pharmacology, publishing and peer review.
Heyden et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: